

## Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis

Ahmed, Shanzay; Mahony, Christopher B.; Torres, Alyssa; Murillo-Saich, Jessica; Kemble, Samuel; Cedeno, Martha; John, Peter; Bhatti, Attya; Croft, Adam P.; Guma, Monica

DOI:

[10.1186/s13075-023-03161-0](https://doi.org/10.1186/s13075-023-03161-0)

License:

Creative Commons: Attribution (CC BY)

### Document Version

Publisher's PDF, also known as Version of record

### Citation for published version (Harvard):

Ahmed, S, Mahony, CB, Torres, A, Murillo-Saich, J, Kemble, S, Cedeno, M, John, P, Bhatti, A, Croft, AP & Guma, M 2023, 'Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis', *Arthritis Research & Therapy*, vol. 25, no. 1, 176. <https://doi.org/10.1186/s13075-023-03161-0>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

RESEARCH

Open Access



# Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis

Shanzay Ahmed<sup>1,2</sup>, Christopher B. Mahony<sup>3</sup>, Alyssa Torres<sup>2</sup>, Jessica Murillo-Saich<sup>2</sup>, Samuel Kemble<sup>3</sup>, Martha Cedeno<sup>2</sup>, Peter John<sup>1\*</sup>, Attya Bhatti<sup>1</sup>, Adam P. Croft<sup>3</sup> and Monica Guma<sup>2\*</sup>

## Abstract

**Background** Synovial fibroblasts in rheumatoid arthritis (RAFLS) exhibit a pathological aberration of glycolysis and glutaminolysis. Henceforth, we aimed to investigate if dual inhibition of these pathways by phytochemical compound c28MS has the potential of synergistic therapy for arthritis by targeting both glucose and glutamine metabolism.

**Methods** The presence of HK2 and GLS across various cell types and associated gene expression in human synovial cells and a murine model of arthritis was evaluated by scRNA-seq. The metabolic profiling of RAFLS cells was done using <sup>1</sup>H-nuclear magnetic resonance spectroscopy under glycolytic and glutaminolytic inhibitory conditions by incubating with 3-bromopyruvate, CB839, or dual inhibitor c28MS. FLS functional analysis was conducted under similar conditions. ELISA was employed for the quantification of IL-6, CCL2, and MMP3. K/BxN sera was administered to mice to induce arthritis for in vivo arthritis experiments.

**Results** scRNA-seq analysis revealed that many fibroblasts expressed *Hk2* along with *Gls* with several genes including *Ptgs2*, *Hif1a*, *Timp1*, *Cxcl5*, and *Plod2* only associated with double-positive fibroblasts, suggesting that dual inhibition can be an attractive target for fibroblasts. Metabolomic and functional analysis revealed that c28MS decreased the aggressive behavior of RAFLS by targeting both upregulated glycolysis and glutaminolysis. c28MS administered in vivo significantly decreased the severity of arthritis in the K/BxN model.

**Conclusion** Our findings imply that dual inhibition of glycolysis and glutaminolysis could be an effective approach for the treatment of RA. It also suggests that targeting more than one metabolic pathway can be a novel treatment approach in non-cancer diseases.

**Keywords** Rheumatoid arthritis, Fibroblast-like synoviocytes, Glucose metabolism, Glutamine metabolism, hexokinase, Glutaminase

\*Correspondence:

Peter John

pjohn@asab.nust.edu.pk

Monica Guma

mguma@health.ucsd.edu

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease of the synovial joints. The disorder is best described by swelling, pain, and stiffness of the affected joints thus negatively impacting the life of the affected individuals [1]. The primary location of inflammation is the lining of the membrane of the synovium. Normal fibroblast-like synoviocytes (FLS) adopt a more aggressive phenotype during the pathogenesis of RA. The altered phenotype is more aggressive due to an increase in the production of chemokines, cytokines, and bone and cartilage degrading enzymes [2–4]. Increased invasive and migrative capability is driven by metabolic reprogramming of the RAFLS. Prior metabolomics studies elucidated that a disrupted metabolism is closely associated to the pathology of RA [5, 6]. This is a probable consequence of the augmented biosynthetic and bioenergetic requisites of chronic inflammation coupled with shifts in the availability of nutrition and oxygen for tissues during inflammation [7, 8]. Previous studies have also indicated that metabolic pathways can be novel therapeutic targets for RA [9].

Glucose and glutamine are two predominant nutrients in the cell that provide energy and biomass for cellular growth and proliferation. The breakdown of glucose and glutamine serves as an essential source of carbon intermediates required for the assembly of various macromolecules. In case of the suppression of glucose metabolism, glutamine may serve as a substitute source for energy and biomass [10]. Thus, the inhibition of a single enzyme from the glycolysis or glutaminolysis pathways might not be as efficient therapeutically as dual inhibition of target enzymes. Of note, several studies showed that glycolysis and glutaminolysis are upregulated in RA [8, 9, 11].

At present, the current regimen of medicines for RA includes NSAIDs (nonsteroidal anti-inflammatory drugs), DMARDs (disease-modifying anti-rheumatic drugs), and glucocorticoids. Despite recent improvements in treatment and disease management for RA, existing medications do not fully target the dysregulated functioning of FLS [12]. Among the most common compounds being employed for the inhibition of glycolysis and glutaminolysis are CB839 and 3-bromopyruvate (3BrPy), respectively [9, 13]. While CB839 is a selective inhibitor and is being rigorously explored for its therapeutic potential in clinical trials [9, 14, 15], 3BrPy had limited success in this context [16]. Furthermore, despite HK2 being one of the 3BrPy targets, 3BrPy is known to affect several other enzymes of the glycolysis and TCA cycle [16–19]. This stems an opportunity for the exploration of new and improved therapeutics to either replace or complement existing therapies.

In our previous study [20], we discovered novel compounds with the potential of dual inhibition of key

enzymes of glycolysis and glutaminolysis, i.e., HK2 and GLS. Computational assessment revealed that 28MS inhibits both target enzymes similarly. Hence, the purpose of the undertaken study was *in vitro* and *in vivo* evaluation of the therapeutic efficiency of this compound to determine whether dual inhibition is a better approach to treat RA.

## Methods

### Reagents

Tumor necrosis factor (TNF, 10 ng/ml) was acquired from R&D Systems Inc. CB-839 (300 nM) was purchased from Selleck, 3Bromopyruvate (3BrPy) from Sigma Aldrich, and compound 28MS (c28MS) from Chembridge Corporation.

### Single-cell RNA sequencing from serum transfer-induced arthritis (STIA) model

All animal protocols were authorized by the UK Home Office and implemented in accordance with the UK's Animals (Scientific Procedures) Act of 1986 and the UK Home Office Code of Practice. The research project and all the protocols were permitted by the University of Birmingham Animal Ethics Review Committee who provisioned ethical surveillance of the study. The C57BL/6 mice were obtained from Charles River. All mice utilized for experimental procedures were 8–10-week-old male mice. Single animals were regarded as experimental entities. Induction of STIA was done by intravenous injection consisting of 100  $\mu$ l of serum derived from KRN mice (K/BxN) [21]. Joint thickness of the wrist or ankle was examined using calipers and described as a variation from the baseline. The acuteness of swelling of the joint was calculated employing the AUC analysis of sequential measurements. Complete joints were dissected and transferred into RPMI-1640 (+2% FCS) having collagenase D (Roche) 0.1 g/ml and 0.01 g/ml of DNase I (Sigma-Aldrich). Obtained samples were then incubated for 40 min at 37 °C. This was followed by incubation for 20 min with a medium incorporated with 0.1 g/ml collagenase dispase (Roche) and 0.01 g/ml DNase I. Synovial CD45 negative cells obtained from hind limbs at day 0, day 7 to 9 peak, day 15 resolving, or day 22 resolved, of STIA murine joints (biological replicates  $n=3$ , each was made from of cells extracted from the joints of three different animals) were sorted and subsequently purified using the BD ARIA and finally acquired with the 10 $\times$ Genomics Chromium system. Murine data is available at GSE230145.

Analyses of 3'-scRNAseq were completed as previously described [22], using the same software, functions, and QC thresholds. Further subcluster analysis of the STIA fibroblast subset was completed

using FindNeighbours(), FindClusters() (From Seurat (v4.0.3)). Subcluster identity was assigned based on the top expressing genes calculated using FindAllMarkers(). Human data was obtained from ImmPort (<https://www.immport.org/shared/study/SDY998>). QC metrics used were `genes_detected > 200` and `genes_detected < 5000` percent\_mt\_molecules < 0.25. Full analysis code is available at [chrismahony/Ahmed-et-al.-2023](https://github.com/chrismahony/Ahmed-et-al.-2023) (github.com).

### Human FLS

FLS were obtained from the affected joints of patients diagnosed with RA and undergoing entire joint replacement as described by [23]. RAFLS were cultured in DMEM with 25 mM of glucose (Dulbecco's modified Eagle's medium), not including sodium pyruvate, and supplemented with 10% of the fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (glucose medium). Experiments involving the glutamine dictating conditions (free/low-glucose) were performed with dialyzed FBS (no. A3382001; Gibco) in DMEM without glucose, glutamine, phenol red, or sodium pyruvate (no. A1443001; Gibco). DMEM without glucose and glutamine was supplemented with 6 mM of glutamine for all the experiments involving glucose-free media and 2 mM glucose and 6 mM of glutamine for all experiments using low-glucose media.

### Western blot

RAFLS were treated with compound 28MS and vehicle for 24 or 48 h in glucose or glucose-free media and then pelleted. Total cellular lysates were made by employing ice-cold lysis buffer (0.5 ml of Tris1M (pH7.6), 1.4 ml of 5 M NaCl, 5 ml of NP40 1%, 0.5 ml of 0.5 M EDTA, 0.5 ml of 0.5 mM NaF, 0.2 ml of 0.1 mM Na Orthovanadate, up to 50 ml distilled water), supplemented with protease inhibitors. The concentration of the protein was determined by conducting a Bradford Assay. Fifteen micrograms of protein was loaded and separated on a TGX-gel (BIO-RAD, Cat#4,569,036) and consequently transferred to a suitable PVDF membrane. Membrane blocking was done with 5% skim milk and thereafter incubated with primary antibodies in 5% milk at 4 °C with primary antibodies recognizing HK2 (1:500, Santa Cruz Biotechnology, USA) GLS1 (1:1000, Abcam, USA) and housekeeping alpha Tubulin (1:1000, Sigma, USA). The following day the membrane was then incubated with the appropriate secondary antibody (1:2000) for a period of 2 h at r.t.p (room temperature). Western ECL substrate, a chemiluminescence detection reagent, was used to visualize and detect proteins of interest.

### <sup>1</sup>H-Nuclear Magnetic Resonance (NMR) spectroscopy, acquisition, and processing of spectra

Approximately 600,000 to 800,000 RAFLS were plated and placed in an incubator at 37 °C for 24 h. 1X PBS was used to wash the cells the following day. Appropriate treatment was added to the cells in 10% FBS medium under high (25 mM glucose and 6 mM glutamine) or low-glucose (2 mM glucose and 6 mM glutamine) conditions and incubated again at 37 °C for 24 h. Ensuing this, cells and supernatant were collected for metabolite extraction as described by [8]. The NMR spectra were recorded employing a 600-MHz Bruker Avance III NMR spectrometer, attached to a 1.7-mm triple resonance cryoprobe. The data were collected at the NMR facility at UC San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences. The obtained metabolites were identified and quantified using Chenomx-NMR Suite 9. The software consists of a built-in reference library to identify the peak of the metabolites as per their chemical shifts. The concentration of the metabolites was obtained in accordance with TSP-d4 (# 269,913; Millipore Sigma), used as an internal standard in this experiment. Metabolite concentrations obtained from the pellets were normalized corresponding to their cell count. On the other hand, metabolite concentrations from the supernatant were calculated after deduction from the values of the control in complete DMEM. Negative values would imply that the particular metabolite had been utilized by the respective cells in the culture medium (concentrations of the metabolites are presented in µM).

### Cell viability

Three thousand RAFLS were seeded in triplicates in a 96-well plate. Appropriate conditions were added in glucose (25 mM glucose and 6 mM glutamine) and low-glucose (2 mM glucose and 6 mM glutamine) mediums and incubated for 24 h at 37 °C. The following day 10% MTT dye was added to the wells and dissolved in 200 µl of DMSO after 4 h of incubation. Cell density was recorded at 550 and 690 nm.

### Matrigel invasion

RAFLS were disassociated using 0.05% trypsin and consequently centrifuged at 1200 rpm for 5 min to pellet the cells.  $\sim 1.1 \times 10^6$  to  $1.2 \times 10^6$  cells were washed with media and repelleted. The repelleted cells were then resuspended in 45 µL of matrigel (BD Biosciences, #356,231) and 45 µL of media with no serum. Five microliters of this cell mixture was used to make spheroids. The spheroids were then placed in an incubator at 37 °C for 9 min to settle and solidify. Appropriate treatments were added to the cells under high glucose (25 mM) or glucose-free

conditions in 1% or 10% FBS and incubated for 24 h at 37 °C. Following incubation, the spheroids were fixed by the addition of 4% paraformaldehyde (PFA). The ensuing staining of the spheroids was done using 0.05% crystal violet and imaged at the microscope facility (UCSD School of Medicine Microscopy Core) with a Keyence Fluorescence Microscope. Image J (<https://imagej.nih.gov/ij/>) was used for the quantification of the invaded area.

#### Migration scratch assay

One hundred fifty thousand RAFLS were seeded in a 6-well plate and starved with 0.1% FBS overnight to circumvent proliferation and subsequently scratched using a sterile tip of the pipette to create two cross-sections. The wells were then washed with 1×PBS. Appropriate treatments were added to cells under high glucose (25 mM) or glucose-free conditions in 1% or 10% FBS and incubated for 24 h at 37 °C to allow them to migrate. A decrease in length indicates an increased migration rate into the wound. Cells were then fixed using the 4% paraformaldehyde (PFA) solution, stained afterwards with 0.05% crystal violet, and imaged at the microscope facility (UCSD School of Medicine Microscopy Core) with a Keyence Fluorescence Microscope. Image J (<https://imagej.nih.gov/ij/>) was used for the quantification of the wound margins at both cross-sections by measuring the distance between the cells on either side of the made scratches.

#### MTT assay

Three thousand RAFLS cells were used as seed per well in a 96-multi-well plate. Three replicate wells were established for each condition. The plated cells were starved overnight with 0.1% FBS to prevent proliferation. Cells were washed with 1X PBS and appropriate conditions were added under high (25 mM glucose and 6 mM glutamine) or low-glucose (2 mM glucose and 6 mM glutamine) conditions in 1% or 10% FBS. RA FLS were then allowed to proliferate at 37 °C. On day 5 after the addition of conditions, 10% MTT dye was added to the wells with appropriate conditions. After an incubation period of 4 h crystals were subsequently dissolved in 200 µL DMSO. Ensuing this the optical density was determined at 550 nm and 690 nm with replicates being averaged for each condition.

#### EDU proliferation assay

The Click-iT<sup>®</sup> Plus Edu Imaging Test (Life technologies) kit was used to perform the EdU proliferation assay as per the manufacturer's instructions. Seven thousand RAFLS cells were plated on glass coverslips placed at the bottom of every well of a 24 multi-well plate. The cells were starved overnight with 0.1% FBS, and the following

day, cells were cultured under high (25 mM glucose and 6 mM glutamine) or low-glucose (2 mM glucose and 6 mM glutamine) conditions in 1% or 10% FBS. EdU was added to the cells 24 h after the addition of conditions at a concentration of 10 µM. On the fifth day after the addition of conditions, cells were fixed with 4% PFA, counterstained with Hoechst, and consequently mounted on slides. EdU-positive cells were counted in Hoechst positive for each condition. The pictures of three random areas on each slide were obtained at a microscope facility (UC San Diego School of Medicine Microscopy Core) with a Keyence Fluorescence Microscope.

#### ELISA

Ninety-six multi-well plate was used for seeding 10,000 RAFLS for performing ELISA. For each condition, 3 replicate wells were established. The inhibitors were added under high glucose (25 mM) or glucose-free conditions 1 h prior to TNF alpha stimulation (5 ng/ml) and incubated for 24 h at 37 °C. The next day, the supernatant was aspirated and IL-6, MMP3, and CCL2 (R&D systems) were measured as per the manufacturer's instructions.

#### Serum transfer-induced arthritis (STIA) inhibition with c28MS compound

KRN-T cell receptor–transgenic mice were obtained as a gift from Dr. D. Mathis (Harvard Medical School, Boston, MA) and Dr. C. Benoist (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France). For serum transfer, the sera from grownup arthritic K/BxN mice were combined. 150 µl of K/BxN arthritic serum was injected intraperitoneally in 3 to 4 months old, female C57BL/6 mice. Mice were treated with vehicle and compound 28MS(2.5 mg/kg) from day 0 to 10. Clinical scores were determined in the receiver mice post-serum transfer, as described previously [24]. On day 10 after the injection of serum, the mice were euthanized, and their paws were collected for histopathology. Furthermore, the effect of c28MS was also compared to the standard drug methotrexate (10 mg/kg daily) in male C57BL/6 mice to assess the efficacy of the compound against a standard drug. Clinical score and joint swelling were recorded and taken as a measure to review the efficacy of standard treatment as opposed to alternative treatment.

#### Histopathology

Collected joints from female C57BL/6 were then fixed by employing a formalin fixative, decalcified in CalEx for 24 h, and consequently, paraffin-embedded. The embedded sections of the paw were then stained with dyes hematoxylin and eosin (H&E) and Safranin O [24].

**Statistical analysis**

GraphPad Prism software version 9 was used for statistical analysis. The normality of the data was determined using a D’Agostino-Pearson or Shapiro–Wilk test for normality. Depending upon the normality of the obtained data, Student’s *T*-test or Mann–Whitney were employed to compare between 2 groups. For the analysis of more than two variables, ANOVA (ordinary one-way analysis of variance) or Kruskal–Wallis test was utilized as per the normality of the distribution ensued by Tukey’s or Dunn’s multiple comparisons, as respective post hoc analysis tests. Results were considered significant if the 2-sided *p*-value was less than 0.05. Heatmaps of metabolites were created by using “gplots” package (<https://cran.r-project.org/web/packages/gplots/gplots.pdf>) in R.


**Results**

**Hexokinase- and glutaminase-driven differential gene expression**


We first wanted to establish which cells across the murine synovial stroma express both *Hk2* and *Gls*. To achieve this, we studied scRNA-seq data from digested synovial tissue from the hind limbs of mice at different timepoints of the STIA disease stage (rest: day 0, peak: day 7–9, resolving: day 15, resolved: day 22) and then completed 3’ mRNA sequencing which produced a total of 20,216 cells that passed QC (Fig. 1A) [22]. The main cell types were

then annotated (Fig. 1A) based on marker gene expression as in Torres et al. (2023) [22] and identified that many fibroblasts expressed *Hk2* along with *Gls* (although expression of *Gls* was also noted on vascular cells), which was confirmed by also plotting the gene signature from both genes (Fig. 1A). We then verified these findings in human synovial cells from publicly available data [25], which showed HK2 to be mainly expressed in fibroblasts and monocytes and GLS to be mainly expressed in Fibroblasts and T cells (Fig. 1B). As different subtypes of fibroblasts have been identified to be functionally different in human and murine synovial tissues, we established murine fibroblast subclusters based on marker gene expression (Fig. 1C, D). We then plotted HK2 and GLS expression in the different subtypes of fibroblasts in murine (Fig. 1E) and established human (Fig. 1F) fibroblast subsets. *Hk2* and *Gls* showed co-expression in Gsn\_Cd34 murine fibroblasts (Fig. 1E). This was corroborated by human data from Zhang et al. (2019) where HK2 and GLS are both expressed more highly in their SC-F1 cluster (a CD34 positive cluster) (Fig. 1F), despite the overall weaker expression of HK2.

We then subset murine fibroblasts and segregated them into double-negative (0 reads for *Hk2* and 0 reads for *Gls*), double-positive (>0 reads for *Hk2* and >0 reads for *Gls*), *Gls*-positive (>0 *G* reads), and *Hk2*-positive (>0 *Hk2* reads) (Fig. 2A) and verified this segregation



**Fig. 1** HK2 and GLS are associated with specific synovial fibroblast subsets. **A** scRNA-seq UMAP of all cells sequenced from Torres et al. (2023) [22] along with expression of *Hk2*, *Gls*, and the signature of both genes. **B** Expression of HK2 and GLS in publicly available data from Zhang et al. [25]. **C**, **D** Establishment of STIA fibroblast subclusters. **E** Expression of *Gls* and *Hk2* in STIA fibroblast subclusters. **F** Expression of GLS and HK2 in previously defined fibroblast sub-cluster in human data from [25]




**Fig. 2** Expression of HK2 and GLS is associated with differential gene expression in fibroblasts. **A, B** Segregation of synovial STIA fibroblasts into *Gls*-positive, *Hk2*-positive, double-negative, and double-positive. **C** Proportion of *Gls*-positive, *Hk2*-positive, double-negative, and double-positive cells in STIA fibroblasts. Each dot represents a sample. Statistical significance was completed using one-way ANOVA and Turkey's post hoc test. \*:  $p < 0.05$ , \*\*:  $p < 0.01$ , \*\*\*:  $p < 0.001$ , \*\*\*\*:  $p < 0.0001$ . **D** Heatmap of differentially expressed genes in *Gls*-positive, *Hk2*-positive, double-negative, or double-positive cells compared to all other cells. Expression is an average scaled expression of genes with an adjusted  $P$  value of  $< 0.01$ . **E** GO term enrichment in *Gls*-positive, *Hk2*-positive, double-negative, or double-positive fibroblasts. **F** Expression of selected marker genes in *Gls*-positive, *Hk2*-positive, double-negative, or double-positive fibroblasts from synovial STIA fibroblasts. **G** Expression of selected marker genes in *Gls*-positive, *Hk2*-positive, double-negative, or double-positive fibroblasts from [25]

by examining gene expression of *Hk2* and *Gls* (Fig. 2B). Of interest, the double-positive cells bearing both gene markers increased in number during the peak while the double-negative cells went down (Fig. 2C). Transcriptionally, double-positive fibroblasts showed some overlap in the number of genes expressed by *Hk2*-positive cells and less of genes expressed by *Gls*-positive cells (Fig. 2D) with several genes including *Ptgs2*, *Hif1a*, *Timp1*, *Cxcl5*, and *Plod2* only associated with double-positive fibroblasts. Genes like *Dkk3*, *Bgn*, *Col6A2*, and *Itm2A* were exclusive to *Gls*-positive fibroblasts while *Maff*, *Cdkn1a*, and *Socs3* were unique only to *Hk2* fibroblasts. Inflammatory-related genes like *IL-6*, *Cxcl1*, *Ccl7*, and *Myc* were common between *Hk2*-positive and double-positive fibroblasts. Moreover, genes associated with the extracellular matrix ECM-like *Col1A2* and *Col1A1* were overlapping between *Gls*-positive and double-positive fibroblasts (Supplementary file 1). GO term analysis showed that *Hk2*-positive cells were more inflammatory associated, double-negative were more associated with

negative regulation of cell migration, and double-positive and *Gls*-positive were more associated with ECM modulation (Fig. 2F). In particular, murine double-positive fibroblasts were enriched in *Has1*, *Col12a1*, and *Col3a1*, and double-negative cells were more associated with *Itm2b*, *Angptl7*, and *Igfbp6*. We also segregated the fibroblasts from Zhang et al. (2019) using the same methodology (Supplementary Fig. S1A–C) to confirm our findings (Fig. 2G).

### Modulation of glucose and glutamine metabolism

To study the effect of inhibiting both enzymes in RAFLS, we first determined whether our compound inhibits glucose and glutamine metabolism. Western blot revealed that compound 28MS (c28MS) did not affect the expression of target enzymes HK2 or GLS1 in both media with and without glucose, suggesting only potential blockage of target enzymes without affecting their respective expressions (Fig. 3A). Metabolic profiling revealed that both 3-bromopyruvate (3BrPy), a non-specific HK



**Fig. 3** Therapeutic inhibition of glycolysis and glutaminolysis. **A** Representative western blot showing that the expression of HK2 and GLS1 in glucose and glucose-free media remains unaffected by the action of c28MS in RAFLS ( $n=3$ ). **B** Color scale encoded heat map illustrating variations in the concentration of key metabolites in RAFLS ( $n=3$ ) between control and treatment groups in glucose medium (glucose medium; 25 mM of glucose and 6 mM of glutamine). **C** Color scale encoded heat map illustrating variations in the concentration of key metabolites in RAFLS ( $n=3$ ) between control and treatment groups in low-glucose medium (2 mM of glucose and 6 mM of glutamine). **D** One-dimensional H<sup>1</sup> nuclear magnetic resonance spectrum fold change in glucose and lactate levels in glucose medium (25 mM of glucose and 6 mM of glutamine) and glutamate and glutamine in low-glucose medium (2 mM of glucose and 6 mM of glutamine) of treated and untreated RAFLS ( $n=3$ ). Values are expressed as mean  $\pm$  standard error mean.  $p < 0.05$  was considered statistically significant

inhibitor, and c28MS were highly effective in reducing the amount of available glucose and consequently lactate for downstream processing to the cells in glucose media. CB839, a glutaminase inhibitor, showed little to no effect in reducing the available amount of glucose to the cells. We also assessed the fold change levels of lactate in the pellet and supernatant and found that the c28MS significantly diminished the lactate levels in the supernatant. In the presence of glucose, CB839, a glutaminase inhibitor, marginally raised the glutamine levels and reduced the glutamate levels. This effect was however not observed by c28MS and 3BrPy in the presence of glucose (Fig. 3B, D). Under low concentrations of glucose, CB839 was highly effective in increasing the glutamine and reducing the glutamate levels in the cells followed by c28MS. In contrast, 3BrPy acted to reduce the glutamine levels and increase the glutamate levels in the cells (Fig. 3C–D). Furthermore, in an abundance of glucose, a general escalation of choline, glycine, and tryptophan because of treatment of 3BrPy and c28MS was observed. Moreover, acetate, betaine, butyrate, cysteine histidine, leucine, isoleucine, methionine, phenylalanine, threonine, tyrosine, and valine were downregulated. However, the effect of c28MS on citrate, alanine, arginine, asparagine, formate, and lysine in the presence of glucose was not synonymous with 3BrPy (Supplementary Fig. S2A). Under low-glucose conditions, treatment with CB839 and the c28MS

increased acetate, alanine, betaine, formate, histidine, isocitrate isoleucine, o-phosphocholine, tryptophan, and valine whereas phenylalanine, proline, and tyrosine were reduced. Regulation of other metabolites was affected differently by the action of CB839 and the compound in glucose-free media (Supplementary Fig S2B).

### Inhibiting the glucose and glutamine metabolism by c28MS reduces RAFLS invasion, migration, and proliferation

Obstructing the elevated glucose and glutamine metabolism itself has been known to diminish the aggressive baneful behavior of RAFLSs by reducing their invading, migrating, and proliferating capability. Our results showed that the cells remained viable at a working concentration of less than 5 $\mu$ M for the compound under study (Supplementary Fig. S3A). Matrigel invasion was used to evaluate the effect of the compound on the invading capacity of the RAFLS in a glucose medium. Our results show that both the c28MS and 3BrPy effectively acted to reduce the escalated invasion of RAFLS in comparison to the control in glucose media. CB839 did little to nullify the invading proclivity of the RAFLS in glucose media (Fig. 4A, B). In the presence of glucose, both 3BrPy and c28MS were effective in reducing the migration of the aggressive RAFLS (Fig. 4C, D). Proliferation is one of the hallmarks of aggressive cells like RAFLS. Inhibition of



the proliferating capacity was evaluated by MTT and further attested by EdU Assay. MTT revealed that only the treatment with 3BrPy and c28MS impaired the escalated proliferation of RAFLS under glucose conditions, with c28MS leading to 3BrPy. However, CB839 was not effective in lessening the proliferation under these conditions. A similar activity pattern suggesting a high anti-proliferative effect of 3BrPy and c28MS and limited anti-proliferative effect of CB839 under glucose concentrations was further verified by EdU assay (Fig. 4E, F). Glucose deprivation potentially enhances glutamine metabolism. Blocking glutamine metabolism is known to deescalate the aggressiveness of RAFLS. To further strengthen the efficacy of c28MS as a glutaminase inhibitor, its effect on invasion, migration, and proliferation in glucose-free/low-glucose conditions was assessed. Like our results in medium with high glucose, the cells remained viable at a working concentration of less than 5  $\mu$ M for the compound under study even under low-glucose conditions (Supplementary Fig. S3B). Under glucose-deprived conditions, both standard treatments CB839, 3BrPy, and c28MS markedly decreased the matrigel invasion and migrative capabilities of the RAFLS (Fig. 4G–J). Of interest, c28MS was more effective in decreasing RAFLS proliferation than CB839 under glucose-deprived conditions (Fig. 4K, L).

#### Blocking glucose and glutamine consumption modulates the TNF-induced IL-6, MMP-3, and CCL2 production in RAFLS

The differentially expressed genes in murine STIA double-positive fibroblasts (Supplementary file 2) were examined by comparing peak inflammation (d7-9)/resolving (d15)/resolved (d22) time points to resting (d0). We found that at peak, the expression of *Ccl2* and *Mmp3* were enriched in the double-positive fibroblasts, suggesting that these may be the main effector molecules in these cells that drive inflammation. The enrichment of *Mmp3* continued in resolving and was lost in resolved (Fig. 5A, Supplementary Fig. S4).

Subsequently, taking the detected presence of MMP3, IL-6, and CCL2 in different phases of the diseases, we


next aimed to evaluate the effect of our treatments on the levels of these molecules under glucose and glutamine-enriched conditions. In the presence of glucose, 3BrPy was the most effective treatment in significantly reducing the detrimental levels of IL-6, CCL2, and MMP3. c28MS was also able to reduce the strikingly high levels of all three pathogenic markers in RAFLS after TNF stimulation. However, like most of our other results, ensuing to the presence of glucose, CB839 had limited efficacy in reducing the escalated levels of IL-6, CCL2, and MMP3 (Fig. 5B–D). The reduction of both IL-6 and CCL2 was more striking in glucose-deprived conditions as all three treatments significantly diminished the burgeoning levels of both IL-6 and CCL2 (Fig. 5E, F). Moreover, in the absence of glucose, only the c28MS compound worked effectively to reduce the MMP3 levels in comparison to all other treatments (Fig. 5G).

#### c28MS significantly decreased arthritis severity in mice

The K/BxN serum transfer-induced arthritis (STIA) model is a robust arthritis model that allows the study of the effector phase of RA. As depicted by the decrease in clinical and histological scores in the K/BxN model (Fig. 6A, B) c28MS prevented the development of arthritis. Robust joint inflammation was observed in the control group whereas it was absent in the group treated with the compound. Importantly, treatment with c28MS averted the development of arthritis, and positively repressed joint swelling in the established mice model. The histological score showed that on day 10 of arthritis, the joints exhibited distinctly diminished cellular infiltration and cartilage and bone damage in animals treated with c28MS in contrast to animals treated with vehicle only (Fig. 6C). We also compared the effect of c28MS with methotrexate. c28MS reduced the clinical score right from the beginning of the treatment, whereas methotrexate began to exhibit a significant effect by reducing the clinical score on day 4 (Fig. 6D). Both treatments, however, were quite comparable in terms of decreased paw swelling (Fig. 6E).

(See figure on next page.)

**Fig. 4** Functional assays to establish inhibitory effects of c28MS and standard treatments in RAFLS in glucose and glucose-free/low-glucose medium (CB839: 300 nm, 3BrPy: 25 $\mu$ M, c28MS: 2 $\mu$ M). **A–D, H–K** RAFLS ( $n=3$ ) were plated for matrigel invasion and migration scratch assay in glucose and glucose-free medium. Quantification of the results (**A, C, H, J**) and representative images of RAFLS invasion and migration (**B, D, I, K**) are shown. **E, L** RAFLS ( $n=3$ ) were plated and starved overnight with 0.1% fetal bovine serum (FBS) and inhibitors added the following day in high-glucose (25 mM) and low-glucose (2 mM) medium. MTT was added on day 5 after the addition of conditions. RAFLS ( $n=3$ ) were starved overnight 0.1% FBS after plating. Compound and standard treatments were added in 1% and 10% FBS media under high-glucose (25 mM) and low-glucose (2 mM) and left to proliferate for 4 days in the presence of EdU and consequently counterstained with Hoechst 33,342 (blue) dye to assess the total proportion of cells. **F, M** Results were quantified as the percentage of EdU-positive cells among the total number of Hoechst 33,342-positive cells and representative images shown in **G** and **N**. Horizontal lines and error bars show the mean  $\pm$  SD. \* =  $p < 0.05$ ; \*\*\*\* =  $p < 0.0001$




**Fig. 4** (See legend on previous page.)

**Discussion**

Targeting metabolism in cancer cells by dual inhibitors has drawn remarkable attention [26–28]. However, the

scope of a similar approach has not been fully explored in RA. Therefore, the undertaken study evaluates the dual inhibition of glycolysis and glutaminolysis using a




**Fig. 5** Effect of treatment on the levels of disease markers identified by scRNA-seq. **A** Volcano plots exhibiting the presence of IL-6, CCL2, and MMP3 between the indicated stages of disease in *Hk2*- and *Gls*- (*double-positive*) positive cells. Each dot represents a gene. Genes in red: adjusted  $p$  value  $< 0.05$  and foldchange  $> 0.5$  and  $< -0.5$ .  $p$  value calculated using FindMarkers() (Seurat). RAFLS ( $n=3$ ) were incubated with vehicle and inhibitors (CB839 (300 nM), 3BrPy (25  $\mu$ M), and c28MS (2  $\mu$ M)) for 1 h followed by stimulation with TNF (5 ng/mL) for 24 h. The production of IL-6, CCL2, and MMP-3 in the culture supernatants of RAFLS ( $n=3$ ) was measured using commercially available ELISA kits in the presence (**B–D**) or absence (**E–G**) of glucose. Values are mean  $\pm$  standard error mean.  $p < 0.05$  was considered statistically different

small drug like the c28MS compound. Based on the data of our study we propose that simultaneous inhibition of these metabolic pathways could complement existing RA treatments by suppressing the pathological behavior of the FLS. Although the molecule might target various cell types, the current study focuses solely on the effect of co-inhibiting HK2 and GLS on FLS.

Dual inhibition is beneficial in complex disorders like RA because the therapeutic regulation of a single pathway may not be as efficient to achieve the desired treatment results. Synergistic inhibition by dual or multi-target agents seems plausible as they can avert the shortcomings of current combination therapies such as side effects, drug interactions, or resistant pathways [29]. Due to the diversity of cellular pathways, exploring the

effect of a dual inhibitor in a non-metabolic scenario has been the focus of some studies. The inhibition of targets like SYK and JAK3 or IL-17 and TNF by action of dual inhibitors in RA has been described [30–32]. The anti-inflammatory dual 5LOX-COX inhibitor has also been the focus of many studies [33–35]. Other research has also reported a similar non-metabolic target, dual inhibition approach for diseases like cancer and Alzheimer’s [36–40].

PI3K/Akt/mTOR, JAK-STAT, AMPK, and Wnt/ $\beta$ -catenin pathways have been strongly implicated with cancer metabolism. The PI3K/Akt/mTOR pathway dual inhibitors have exhibited a promising therapeutic effect [41–44] in cancer. Yang et al. reported a dual inhibitor of AMPK and WNT/ $\beta$ -catenin which displayed promising



**Fig. 6** Treatment with c28MS decreases clinical scores and histologic scores in the K/BxN mouse model of arthritis. **A** Clinical scores were determined in vehicle-treated animals ( $n=5$ ) and c28MS-treated animals ( $n=5$ ) at a dose of 2.5 mg/kg. One hundred fifty microliters of K/BxN mouse serum was injected at day 0 and treatment was administered intraperitoneally daily from day 0 and continued until day 10. **B** Histologic scores were determined on day 10 after serum transfer in vehicle-treated or c28MS-treated mice. **C** Sections of the ankle joints of vehicle or c28MS-treated mice were stained with hematoxylin and eosin (H&E) or Safranin O on day 10 after arthritis induction. Black arrows indicate joint inflammation and hypertrophy, and yellow arrows highlight cartilage damage, which was reduced in c28MS-treated mouse ankles. **D, E** Induction of arthritis and treatment (c28MS and MTX) prognosis in treated and untreated K/BxN mice model ( $n=5$  per group) **D** clinical score and **E** paw swelling. Horizontal lines and error bars show the mean  $\pm$  SD. \* =  $p < 0.05$ , \*\*\*\* =  $p < 0.0001$

anti-cancer activity against colorectal cancer [45]. The repression of HDAC- JAK and AMPK-MELK by action of dual inhibitors has also proved effective in vitro and in vivo [46, 47]. Despite the reported efficacy of these inhibitors, further research is needed for validation. And like all therapies, this approach has its downfalls as well, such as a lack of predictive biomarkers for the assessment of the treatment's effectiveness, toxicity, or variance in efficacy according to the type of cancer [41].

In our work, we suggest fibroblasts as specific target cells for the safe and reliable synergistic suppression of glycolysis and glutaminolysis. Targeting fibroblasts would prevent the needless tampering of the immune system and preclude the possible repercussions of global glycolytic and glutaminolytic inhibition. Of interest, HK2 was mostly expressed in macrophages and fibroblasts and showed to be dispensable in T cells, yet GLS1 is crucial in T cell immunity [48–51]. Our study findings elucidate that HK2 and GLS are two distinct pathways that drive various genes involved in vital cellular processes, inflammatory cascades, response to stimuli, ECM components, and remodeling. The results of our study indicate a more prominent expression of HK2 and GLS in sub-lining fibroblast cluster/clusters. The inducible nature of HK2 [23, 52] is further strengthened by our results as the number of HK2-positive cells increases at the peak of the disease in comparison to the baseline/resting phase of the disease. Furthermore, the number of double-positive cells also increases as a result of the inflammation further

suggesting HK2 and GLS as players of the pathological metabolism in RA. Thus, obstructing both targets with a dual inhibitor would offer better control of RA.

Additionally, the detection of genes like *Ptgs2*, *Cxcl5*, *Timp1*, and *Hif1a* solely on double-positive fibroblasts also strengthens our concept of synergistic inhibition in RA [8, 53–58]. Other genes such as *Has*, *Postn*, *Plod2*, and *Phlda1* were detected in *Hk2*, *Gls*, and double-positive fibroblasts (Supplementary Table 1). These genes have been linked to the aggressive behavior of cells in RA and other disorders [8, 59–63]. Consistently, c28MS reduced the invasion, migration, and proliferation, regardless of the concentration of glucose in the RAFLS. In addition, the compound also modified the cytokine profile, which was relatively more affected by glutamine metabolism inhibition than glucose metabolism inhibition. The existing literature is heterogenous when it comes to glutamine metabolism affecting the cytokine profile [8, 64] whereas glucose starvation has been known to reduce the amounts of the inflammatory cytokines like IL-6, in addition to degradative enzymes like MMP1 and MMP3 [65].

According to our findings, concurrent expression of HK2 and GLS was observed in many fibroblasts, with each gene governing distinct pathways that lead to the development and subsequent progression in RA. Decreasing glucose and/or glutamine has been shown to be therapeutically important [11, 66]. Our findings indicate that inhibiting both glycolysis and glutaminolysis is more beneficial than solely

inhibiting glutaminolysis with CB839. However, we were unable to establish that our compound is superior to 3BrPy, possibly due to 3BrPy's ability to act on multiple enzymes beyond HK2. Additional targets of 3BrPy include lactate dehydrogenase (LDH), pyruvate dehydrogenase, isocitrate dehydrogenase (IDH), and alpha-ketoglutarate dehydrogenase [17, 18]. However, c28MS and 3BrPy displayed a fair degree of similarity in their ability to inhibit HK2 thereby suppressing glycolysis and c28MS decreased intracellular glucose and lactate levels in the presence of glucose-like 3BrPy. Interestingly, in the presence of glucose, unlike CB839, the capacity of the compound to obstruct extensive glutamine consumption was hindered. However, the capability of the compound to block glutamine metabolism was only accentuated under low-glucose conditions. Although our NMR results showed that CB839 did not reduce the lactate levels in RAFLS, Zacharias et al. reported that obstruction of glutaminase activity by the action of CB839 has been shown to reduce the amount of lactate in AML (acute myeloid leukemia) [67]. Additionally, the CB839 treatment has been shown to reduce glucose and lactate uptake in head and neck cancer [68]. This may indicate that non-tumor cell metabolism is different than cancer cells.

The KxB/N model of passive arthritis is highly reliant on FLS and other cells like neutrophils, macrophages, and mast cells [69]. Histological and clinical scores and paw swelling indicated that the compound successfully suppressed inflammatory arthritis both when injected before the arthritis induction and at the arthritis peak. This implies not only a protective but also a therapeutic effect of the compound, which was similar to the effect of methotrexate, thus providing an alternative treatment for RA [70].

In summary, we report that targeting glycolysis and glutaminolysis can be therapeutically more promising as this may modify potential cross-talk amid FLS and other neighboring adjacent cells inhabiting the synovium in contrast to when either of the pathways is inhibited alone. This could complement the existing therapies for RA thereby improving disease outcomes. The acquired data can further find its extension on other rheumatic disorders.

## Conclusion

Our study results propose that glutaminolytic and glycolytic pathways are upregulated in RAFLS and that dual inhibition of excessive consumption of glucose and glutamine could be an effective approach for the treatment of RA by suppressing the aggressive properties of

RAFLS. The suppression of glycolysis and glutaminolysis by the action of a dual inhibitor tends to remain a lesser-explored therapeutic approach for RA. Hence, this data provides a potential priming ground for therapeutic suppression of both glycolysis and glutaminolysis for RA and other rheumatic diseases.

## Abbreviations

RA	Rheumatoid Arthritis
RAFLS	Rheumatoid Arthritis Fibroblast-like Synoviocytes
FLS	Fibroblast-like Synoviocytes
DMEM	Dulbecco's Modified Eagle's Medium
PBS	Phosphate Buffer Saline
HK2	Hexokinase 2
GLS	Glutaminase
LDH	Lactate Dehydrogenase
PDH	Pyruvate Dehydrogenase
IDH	Isocitrate Dehydrogenase
ELISA	Enzyme-linked Immunosorbent Assay
NMR	Nuclear Magnetic Resonance
EdU Proliferation	(5-Ethynyl-2'-deoxyuridine) Proliferation Assay
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
GEO	Gene Expression Omnibus
AUC	Area under the curve
STIA	Serum Transfer-Induced Arthritis

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13075-023-03161-0>.

**Additional file 1: Figure S1.** A scRNA-seq UMAP of all cells sequenced as described in Zhang et al., 2019 [25]. B,C Segregation of synovial fibroblasts from Zhang et al., 2019 [25] in to GLS positive, HK2 positive, double negative and double positive cells.

**Additional file 2: Figure S2.** Color scale encoded heat maps illustrating variations in the concentration of various metabolites between control and treatment groups in RAFLS A glucose medium (25mM of glucose and 6mM of glutamine) and B low glucose medium (2mM of glucose and 6mM of glutamine) respectively.

**Additional file 3: Figure S3.** Effect of c28MS on viability of RAFLS (n=3) A glucose medium (25mM of glucose and 6mM of glutamine) and B low glucose medium (2mM of glucose and 6mM of glutamine).

**Additional file 4: Figure S4.** Expression of *Ccl2*, *Mmp3* and *Il6* in double positive and negative fibroblasts at different stages of the disease.

**Additional file 5.** Details of genes found in double negative, HK2 positive, GLS positive and double positive fibroblasts in murine STIA.

**Additional file 6.** List of up-and down regulated genes in double positive fibroblasts for the different disease stages.

## Acknowledgements

Not applicable.

## Authors' contributions

MG, PJ and AB supervised and co-supervised the overall project. SA, MG and PJ conceptualized and designed the undertaken study. SA, CBM, SK, JMS, AT, MC acquired the data. SA, CBM, SK, MG, APC analyzed and interpreted the acquired data. SA, CBM, MG, PJ, AB, APC wrote the overall manuscript. All authors were involved in drafting the manuscript, or revising or reviewing it critically for important intellectual content. All authors read and approved the final version to be published. Dr. Guma had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

## Funding

This research work was supported by the Higher Education Commission, Pakistan under the International Research Support Initiative Program (IRSIP). Monica Guma was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health (R01AR073324). Adam Croft was funded by the Kennedy Trust for Rheumatology Research Senior Fellowship (KENN 19 20 06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Availability of data and materials

The data that support the findings in the study are included in the article/Supplementary material. Further inquiries can be directed to the corresponding author.

## Declarations

### Ethics approval and consent to participate

All animal protocols were authorized by the UK Home Office and implemented in accordance with the UK's Animals (Scientific Procedures) Act of 1986 and the UK Home Office Code of Practice. The research project and all the protocols were permitted by the University of Birmingham Animal Ethics Review Committee who provisioned ethical surveillance of the study. Furthermore, all experimental protocols involving the testing of c28MS in the STIA model stood as per the international guidelines of the IASP and Animals Scientific Procedure Act, 1986, and duly authorized by the Institutional Review Board. Guide for the Care and Use of Laboratory Animals from the Institute for Laboratory Animal Research (National Research Council). FLS were obtained from patients undergoing total knee replacement after informed consent.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Department of Healthcare Biotechnology, Atta-Ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad 44000, Pakistan. <sup>2</sup>Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, USA. <sup>3</sup>Rheumatology Research Group, Institute of Inflammation and Ageing, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK.

Received: 23 May 2023 Accepted: 1 September 2023

Published online: 20 September 2023

## References

- Macfarlane FR, Chaplain MA, Eftimie R. Modelling rheumatoid arthritis: a hybrid modelling framework to describe pannus formation in a small joint. *ImmunInformatics*. 2022;6: 100014.
- Mousavi MJ, Karami J, Aslani S, Tahmasebi MN, Vaziri AS, Jamshidi A, Farhadi E, Mahmoudi M. Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. *Autoimmunity Highlights*. 2021;12(1):1–13.
- Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. *Nat Rev Rheumatol*. 2020;16(6):316–33.
- Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. *Nat Rev Rheumatol*. 2013;9(1):24–33.
- Falconer J, Murphy AN, Young SP, Clark AR, Tiziani S, Guma M, Buckley CD. Synovial cell metabolism and chronic inflammation in rheumatoid arthritis. *Arthritis Rheumatol*. 2018;70(7):984–99.
- Weyand CM, Goronzy JJ. Immunometabolism in the development of rheumatoid arthritis. *Immunol Rev*. 2020;294(1):177–87.
- Henderson B, Bitensky L, Chayen J. Glycolytic activity in human synovial lining cells in rheumatoid arthritis. *Ann Rheum Dis*. 1979;38(1):63–7.
- Torres A, Pedersen B, Cobo I, Ai R, Coras R, Murillo-Saich J, Nygaard G, Sanchez-Lopez E, Murphy A, Wang W, Firestein GS, Guma M. Epigenetic regulation of nutrient transporters in rheumatoid arthritis fibroblast-like synoviocytes. *Arthritis Rheumatol*. 2022;74(7):1159–71.
- Sanchez-Lopez E, Cheng A, Guma M. Can metabolic pathways be therapeutic targets in rheumatoid arthritis? *J Clin Med*. 2019;8(5):753.
- Xu Y, Yu Z, Fu H, Guo Y, Hu P, Shi J. Dual inhibitions on glucose/glutamine metabolisms for nontoxic pancreatic cancer therapy. *ACS Appl Mater Interfaces*. 2022;14(19):21836–47.
- Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis. *Front Immunol*. 2019;10:1743.
- Li J, Pang J, Liu Z, Ge X, Zhen Y, Jiang CC, Liu Y, Huo Q, Sun Y, Liu H. Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways. *Sci Rep*. 2021;11(1):1–13.
- Yadav S, Pandey SK, Singh VK, Goel Y, Kumar A, Singh SM. Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: implication in designing of novel anticancer therapeutic strategies. *PLoS ONE*. 2017;12(5): e0176403.
- Zhao Y, Feng X, Chen Y, Selfridge JE, Gorityala S, Du Z, Wang JM, Hao Y, Cioffi G, Conlon RA. 5-Fluorouracil enhances the antitumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers. *Can Res*. 2020;80(21):4815–27.
- Riess JW, Frankel P, Shackelford D, Dunphy M, Badawi RD, Nardo L, Cherry SR, Lanza I, Reid J, Gonsalves WI. Phase 1 trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in patients with advanced NSCLC (NCI 10327): rationale and study design. *Clin Lung Cancer*. 2021;22(1):67–70.
- Yadav S, Pandey SK, Goel Y, Temre MK, Singh SM. Diverse stakeholders of tumor metabolism: an appraisal of the emerging approach of multifaceted metabolic targeting by 3-bromopyruvate. *Front Pharmacol*. 2019;10:728.
- Fan T, Sun G, Sun X, Zhao L, Zhong R, Peng Y. Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumor treatment. *Cancers*. 2019;11(3):317.
- Cal M, Matyjaszczyk I, Litwin I, Augustyniak D, Ogórek R, Ko Y, Ułaszewski S. The anticancer drug 3-bromopyruvate induces DNA damage potentially through reactive oxygen species in yeast and in human cancer cells. *Cells*. 2020;9(5):1161.
- Jardim-Messeder D, Moreira-Pacheco F. 3-Bromopyruvic acid inhibits tricarboxylic acid cycle and glutaminolysis in HepG2 cells. *Anticancer Res*. 2016;36(5):2233–41.
- Ahmed S, John P, Paracha RZ, Bhatti A, Guma M. Docking and molecular dynamics study to identify novel phytochemicals from *Dracaena trifasciata* against metabolic reprogramming in rheumatoid arthritis. *Life*. 2022;12(8):1148.
- Kollias G, Papadaki P, Apparailly F, Vervordeldonk MJ, Holmdahl R, Baumans V, Desaintes C, Di Santo J, Distler J, Garside P. Animal models for arthritis: innovative tools for prevention and treatment. *Ann Rheum Dis*. 2011;70(8):1357–62.
- Torres A, Kang S, Mahony CB, Cedeño M, Oliveira PG, Fernandez-Bustamante M, Kemble S, Laragione T, Gulko PS, Croft AP. Role of mitochondria-bound HK2 in rheumatoid arthritis fibroblast-like synoviocytes. *Front Immunol*. 2023;14. <https://doi.org/10.3389/fimmu.2023.1103231>.
- Bustamante MF, Oliveira PG, Garcia-Carbonell R, Croft AP, Smith JM, Serrano RL, Sanchez-Lopez E, Liu X, Kisseleva T, Hay N. Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis. *Ann Rheum Dis*. 2018;77(11):1636–43.
- Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1 $\beta$  in neutrophil-predominant inflammation. *Arthritis Rheum*. 2009;60(12):3642–50.
- Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabecheian D, Hughes LB, Salomon-Escoto K. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. *Nat Immunol*. 2019;20(7):928–42.
- Lei L, Nan B, Yang F, Xu L, Guan G, Xu J, Yue R, Wang Y, Huan S, Yin X, Zhang X-B, Song G. Zinc-carnosine metallodrug network as dual metabolism inhibitor overcoming metabolic reprogramming for efficient cancer therapy. *Nano Lett*. 2023;23(7):2659–68.
- Wang K, Zhu C, He Y, Zhang Z, Zhou W, Muhammad N, Guo Y, Wang X, Guo Z. Restraining cancer cells by dual metabolic inhibition with a

- mitochondrion-targeted platinum (II) complex. *Angew Chem Int Ed*. 2019;58(14):4638–43.
28. Fang X, Yuan M, Dai J, Lin Q, Lin Y, Wang W, Jiang Y, Wang H, Zhao F, Wu J. Dual inhibition of glycolysis and oxidative phosphorylation by aptamer-based artificial enzyme for synergistic cancer therapy. *Nano Res*. 2022;15(7):6278–87.
  29. Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad S. Dual or multi-targeting inhibitors: the next generation anticancer agents. *Eur J Med Chem*. 2018;143:1277–300.
  30. Kaur M, Singh M, Silakari O. Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation. *Future Med Chem*. 2017;9(11):1193–211.
  31. Koenders MI, van den Berg WB. Novel therapeutic targets in rheumatoid arthritis. *Trends Pharmacol Sci*. 2015;36(4):189–95.
  32. Taams LS. Interleukin-17 in rheumatoid arthritis: trials and tribulations. *J Exp Med*. 2020;217(3):e20192048.
  33. Razavi SM, Khayatan D, Arab ZN, Momtaz S, Zare K, Jafari RM, Dehpour AR, Abdolghaffari AH. Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders. *Prostaglandins Other Lipid Mediat*. 2021;157:106587.
  34. Kulkarni S, Pal Singh V. Licofelone—a novel analgesic and anti-inflammatory agent. *Curr Top Med Chem*. 2007;7(3):251–63.
  35. Martel-Pelletier J, Lajeunesse D, Rebourg P, Pelletier J-P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. *Ann Rheum Dis*. 2003;62(6):501–9.
  36. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. *J Med Chem*. 2002;45(24):5260–79.
  37. Zhang Q, Zhai S, Li L, Li X, Zhou H, Liu A, Su G, Mu Q, Du Y, Yan B. Anti-tumor selectivity of a novel Tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. *Biochem Pharmacol*. 2013;86(3):351–60.
  38. Spicer JA, Gamage SA, Rewcastle GW, Finlay GJ, Bridewell DJ, Baguley BC, Denny WA. Bis (phenazine-1-carboxamides): structure– activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. *J Med Chem*. 2000;43(7):1350–8.
  39. Guerrant W, Patil V, Canzonieri JC, Oyelere AK. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. *J Med Chem*. 2012;55(4):1465–77.
  40. Seo YH. Dual inhibitors against topoisomerases and histone deacetylases. *J Cancer Prev*. 2015;20(2):85.
  41. Chen M, Lan H, Yao S, Jin K, Chen Y. Metabolic interventions in tumor immunity: focus on dual pathway inhibitors. *Cancers*. 2023;15(7):2043.
  42. Occhiuzzi MA, Lico G, Iolele G, De Luca M, Garofalo A, Grande F. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents. *Eur J Med Chem*. 2023;246:114971.
  43. Wu Y-Y, Wu H-C, Wu J-E, Huang K-Y, Yang S-C, Chen S-X, Tsao C-J, Hsu K-F, Chen Y-L, Hong T-M. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. *J Exp Clin Cancer Res*. 2019;38(1):1–16.
  44. Tseng C-Y, Kuo C-Y, Fu Y-H, Hou H-A, Tien H-F, Lin L-I. P422: omipalisib, a dual PI3K/MTOR inhibitor, targets mitochondria and impairs oxidative phosphorylation in acute myeloid leukemia. *HemaSphere*. 2022;6:322–3.
  45. Yang W, Li Y, Ai Y, Obianom ON, Guo D, Yang H, Sakamuru S, Xia M, Shu Y, Xue F. Pyrazole-4-Carboxamide (YW2065): a therapeutic candidate for colorectal cancer via dual activities of Wnt/ $\beta$ -catenin signaling inhibition and AMP-activated protein kinase (AMPK) activation. *J Med Chem*. 2019;62(24):11151–64.
  46. Zhao L, Liang Q, He Y, Liu M, Tong R, Jiang Z, Wang W, Shi J. HDAC/JAK dual target inhibitors of cancer-related targets: the success of nonclearable linked pharmacophore mode. *Bioorganic Chem*. 2022;106181. <https://doi.org/10.1016/j.bioorg.2022.106181>.
  47. Jaune E, Cavazza E, Ronco C, Grytsai O, Abbe P, Tekaya N, Zerhouni M, Beranger G, Kaminski L, Bost F. Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. *Cell Death Dis*. 2021;12(1):64.
  48. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishiton RJ. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. *Cell*. 2018;175(7):1780–1795. e1719.
  49. Xu T, Stewart KM, Wang X, Liu K, Xie M, Ryu JK, Li K, Ma T, Wang H, Ni L. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. *Nature*. 2017;548(7666):228–33.
  50. Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI. Glutamine-dependent  $\alpha$ -ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. *Sci Signal*. 2015;8(396):ra97-ra97.
  51. Mehta MM, Weinberg SE, Steinert EM, Chhiba K, Martinez CA, Gao P, Perlman HR, Bryce P, Hay N, Chandel NS. Hexokinase 2 is dispensable for T cell-dependent immunity. *Cancer Metab*. 2018;6(1):1–18.
  52. Xian H, Bao X, Zhang H, Wei F, Song Y, Wang Y, Wei Y, Wang Y. Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2/mTORC1-induced autophagy. *Int Immunopharmacol*. 2023;114:109556.
  53. Wei Q, Lv F, Zhang H, Wang X, Geng Q, Zhang X, Li T, Wang S, Wang Y, Cui Y. MicroRNA-101-3p inhibits fibroblast-like synovioyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2. *Biosci Rep*. 2020;40(1):BSR20191136. <https://doi.org/10.1042/BSR20191136>.
  54. Ding Y, Wang L, Wu H, Zhao Q, Wu S. Exosomes derived from synovial fibroblasts under hypoxia aggravate rheumatoid arthritis by regulating Treg/Th17 balance. *Exp Biol Med*. 2020;245(14):1177–86.
  55. Brouwer E, Gouw A, Posthumus M, Van Leeuwen M, Boerboom AL, Bijzet J, Bos R, Limburg P, Kallenberg C, Westra J. Hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) is related to both angiogenesis and inflammation in rheumatoid arthritis. *Clin Exp Rheumatol*. 2009;27(6):945–51.
  56. Smith E, McGettrick HM, Stone MA, Shaw JS, Middleton J, Nash GB, Buckley CD, Ed Rainger G. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. *Arthritis Rheum*. 2008;58(7):1968–1973.
  57. Tejera-Segura B, Lopez-Mejias R, de Vera-Gonzalez A, Delgado-Gonzalez A, González-Gay MA, Ferraz-Amaro I. Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2019;37(3):373–9.
  58. Burkhardt J, Petit-Teixeira E, Teixeira VH, Kirsten H, Garnier S, Ruehle S, Oeser C, Wolfram G, Scholz M, Migliorini P. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. *J Rheumatol*. 2009;36(10):2149–57.
  59. Du H, Chen Y, Hou X, Huang Y, Wei X, Yu X, Feng S, Wu Y, Zhan M, Shi X. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. *Cell Death Dis*. 2017;8(10):e3143–e3143.
  60. You S, Yoo S-A, Choi S, Kim J-Y, Park S-J, Ji J-D, Kim T-H, Kim K-J, Cho C-S, Hwang D. Identification of key regulators for the migration and invasion of rheumatoid synoviocytes through a systems approach. *Proc Natl Acad Sci*. 2014;111(1):550–5.
  61. Chan DD, Xiao W, Li J, de la Motte CA, Sandy JD, Plaas A. Deficiency of hyaluronan synthase 1 (Has1) results in chronic joint inflammation and widespread intra-articular fibrosis in a murine model of knee joint cartilage damage. *Osteoarthritis Cartilage*. 2015;23(11):1879–89.
  62. Xu J, Bi G, Luo Q, Liu Y, Liu T, Li L, Zeng Q, Wang Q, Wang Y, Yu J. PHLDA1 modulates the endoplasmic reticulum stress response and is required for resistance to oxidative stress-induced cell death in human ovarian cancer cells. *J Cancer*. 2021;12(18):5486.
  63. Dolcino M, Ottria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, Beri R, Lunardi C, Puccetti A. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. *PLoS ONE*. 2015;10(6):e0128262.
  64. Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, Li D, Wang L, Chen Y, Liang Y. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. *Cell Communication and Signaling*. 2022;20(1):1–15.
  65. Farah H, Young SP, Mauro C, Jones SW. Metabolic dysfunction and inflammatory disease: The role of stromal fibroblasts. *FEBS J*. 2021;288(19):5555–68.
  66. Takahashi S, Saegusa J, Sendo S, Okano T, Akashi K, Irino Y, Morinobu A. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis. *Arthritis Res Ther*. 2017;19(1):1–10.
  67. Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Lujan JV, Dutta P, Millward SW, Cai T, Wood CG, Piwnicka-Worms D. Assessing metabolic intervention with a glutaminase inhibitor in real-time by hyperpolarized magnetic resonance in acute myeloid leukemia. *Mol Cancer Ther*. 2019;18(11):1937–46.

68. Lang L, Wang F, Ding Z, Zhao X, Loveless R, Xie J, Shay C, Qiu P, Ke Y, Saba NF. Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer. *J Exp Clin Cancer Res.* 2021;40(1):1–14.
69. Guma M, Sanchez-Lopez E, Lodi A, Garcia-Carbonell R, Tiziani S, Karin M, Lacal J, Firestein G. Choline kinase inhibition in rheumatoid arthritis. *Ann Rheum Dis.* 2015;74(7):1399–407.
70. Elsayy H, Alzahrani AM, Alfwuaires M, Abdel-Moneim AM, Khalil M. Nephroprotective effect of naringin in methotrexate induced renal toxicity in male rats. *Biomed Pharmacother.* 2021;143: 112180.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

